Literature DB >> 9422575

Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo.

S Ning1, C Shui, W B Khan, W Benson, D L Lacey, S J Knox.   

Abstract

PURPOSE: Keratinocyte growth factor (KGF) has potent mitogenic activity on normal epithelial cells and has been found to enhance intestinal crypt cell survival in irradiated mice and to prevent radiation and chemotherapy-induced mucositis in animal models. The purpose of the study reported here is to investigate the effect of recombinant human KGF on the proliferation and survival of human squamous carcinoma cell lines following irradiation. METHODS AND MATERIALS: The level of KGF receptor (KGFR) mRNA in normal Balb/Mk cell line and human head and neck squamous carcinoma cell lines was assessed using a RNase protection assay. The clonogenic assay and MTT assay were used to study the proliferative effects of KGF on human tumor cell lines and Balb/MK cell line in vitro. Effects of KGF on in vivo tumor growth and radiosensitivity were studied in three KGFR-positive human squamous cell carcinoma xenografts (FaDu, Detroit 562 and A431) in nude mice, and a murine KGFR-negative melanoma tumor (B16) in Balb/c mice.
RESULTS: Seven of 10 tumor cell lines studied expressed KGFR mRNA. None of these tumor cell lines showed enhanced proliferation when exposed to KGF for 2 days or less. Prolonged exposure to KGF for 7 days or longer resulted in low level stimulation of proliferation in both clonogenic and MTT assays in four of seven KGFR-positive cell lines. Two KGFR-negative cell lines also had a low proliferative response to KGF in a clonogenic assay, but not in the MTT assay. Normal keratinocyte Balb/MK cells, which expressed a moderate level of KGFR mRNA, had a strongly proliferative response to KGF. Its KGF enhancement ratio (KER) of plating efficiency was 24-70 times higher than that of the tumor cells studied (p < 0.001). The KGF-stimulated tumor cell growth was almost completely inhibited by heparin or epidermal growth factor (EGF). There were no significant differences (p > 0.05) in the survival of any of tumor cell lines in the presence or absence of KGF (100 ng/ml) irradiated with doses of 0-15 Gy, and no significant differences (p > 0.05) between the radiobiological parameters D0, Dq, and n number from the SHMT model, alpha, beta, and alpha/beta ratio from the LQ model and SF2 for radiation survival curves for cell lines irradiated in the presence or absence of KGF. Three KGFR-positive human squamous cell carcinoma xenografts in nude mice, and a murine KGFR-negative melanoma tumor in Balb/c mice treated with 1.0 mg/kg of KGF for 3 days grew at the same rate as in untreated mice.
CONCLUSION: The recombinant human KGF resulted in little or no stimulation of the proliferation of human head and neck squamous tumor cell lines and did not affect the radiosensitivity of these cell lines in vitro and in vivo. Therefore, KGF may be of clinical value in preventing radiation-induced mucositis and may have the potential to increase the therapeutic index of radiotherapy for treatment of cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422575     DOI: 10.1016/s0360-3016(97)00561-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation.

Authors:  Ilia A Toshkov; Anatoli S Gleiberman; Vadim L Mett; Alan D Hutson; Anurag K Singh; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  Radiat Res       Date:  2017-03-21       Impact factor: 2.841

Review 2.  Palifermin: in myelotoxic therapy-induced oral mucositis.

Authors:  M Asif A Siddiqui; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effect of tumour-cell-derived or recombinant keratinocyte growth factor (KGF) on proliferation and radioresponse of human epithelial tumour cells (HNSCC) and normal keratinocytes in vitro.

Authors:  Andrea Hille; Susanne Grüger; Hans Christiansen; Hendrik A Wolff; Beate Volkmer; Jörg Lehmann; Wolfgang Dörr; Margret Rave-Fränk
Journal:  Radiat Environ Biophys       Date:  2010-03-07       Impact factor: 1.925

4.  Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease.

Authors:  Heike Steiling; Marcus Mühlbauer; Frauke Bataille; Jürgen Schölmerich; Sabine Werner; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

5.  Differential action of growth hormone in irradiated tumoral and nontumoral intestinal tissue.

Authors:  Juana Morante; María T Vallejo-Cremades; Lourdes Gómez-García; Isabel Vázquez; Ignacio A Gómez-de-Segura; Miriam Sanchez; Enrique De Miguel
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

6.  Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

Authors:  Robert R Jenq; Christopher G King; Christine Volk; David Suh; Odette M Smith; Uttam K Rao; Nury L Yim; Amanda M Holland; Sydney X Lu; Johannes L Zakrzewski; Gabrielle L Goldberg; Adi Diab; Onder Alpdogan; Olaf Penack; Il-Kang Na; Lucy W Kappel; Jedd D Wolchok; Alan N Houghton; Miguel-Angel Perales; Marcel R M van den Brink
Journal:  Blood       Date:  2008-11-14       Impact factor: 22.113

7.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.

Authors:  Mitchell Machtay; Jennifer Moughan; Andrew Trotti; Adam S Garden; Randal S Weber; Jay S Cooper; Arlene Forastiere; K Kian Ang
Journal:  J Clin Oncol       Date:  2008-06-16       Impact factor: 44.544

8.  Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.

Authors:  Mervi Toriseva; Risto Ala-aho; Sirkku Peltonen; Juha Peltonen; Reidar Grénman; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

9.  Palifermin for management of treatment-induced oral mucositis in cancer patients.

Authors:  Andrei Barasch; Joel Epstein; Ken Tilashalski
Journal:  Biologics       Date:  2009-07-13

10.  Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies.

Authors:  J P Hong; S-W Lee; S Y Song; S D Ahn; S S Shin; E K Choi; J H Kim
Journal:  Eur J Cancer Care (Engl)       Date:  2009-04-23       Impact factor: 2.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.